IP Library Granted Patent US 12,491,202
Granted Patent B2
US 12,491,202 · App. 17/480,239 · Granted Dec 9, 2025

Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors

Inventors: Mario Otto (Fitchburg, WI); Dana C. Baiu (Madison, WI); Bryan P. Bednarz (Madison, WI); Jamey Paul Weichert (Sun Prairie, WI)
Assignee: Wisconsin Alumni Research Foundation
A61K31/685A61K31/6615A61K31/69A61K33/18G01N33/57407G01N33/57484
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,491,202
App. No.
17/480,239
Granted
Dec 9, 2025
Kind
B2
Abstract

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R 2 is —N + (CH 3 ) 3 . The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R 1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R 1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.

Claims (19)

1 . A method for treating a malignant pediatric solid tumor in a subject, comprising administering to the subject having the malignant pediatric solid tumor an effective amount of a compound having the formula:

or a salt thereof, wherein:

R1 comprises a radioactive iodine isotope;

n is an integer from 12 to 24; and

R2 is —N + (CH3)3;

whereby the malignant pediatric solid tumor is treated in the subject.

2 . The method of claim 1 , wherein the radioactive iodine isotope is selected from the group consisting of 123 I, 125 I and 131 I.

3 . The method of claim 1 , wherein n is 18, and the radioactive iodine isotope is 123 I, 125 I or 131 I (the compound is [ 123 I]-CLR1404, [ 125 I]-CLR1404 or [ 131 I]-CLR1404).

4 . The method of claim 1 , wherein the compound is administered by parenteral, intranasal, sublingual, rectal, or transdermal delivery.

5 . The method of claim 1 , wherein the malignant pediatric solid tumor that is treated is selected from the group consisting of neuroblastoma (NB), Ewings sarcoma (EWS), osteosarcoma (OS), retinoblastoma (RB) Wilms' tumor (WT), and pediatric brain tumors.

6 . A method for inhibiting the proliferation or growth of malignant pediatric solid tumor cells, comprising contacting one or more malignant pediatric solid tumor cells with an effective amount of a compound having the formula:

or a salt thereof, wherein:

R1 comprises a radioactive iodine isotope;

n is an integer from 12 to 24; and

R2 is —N + (CH3)3;

whereby growth or proliferation of the malignant pediatric solid tumor cells is inhibited.

7 . The method of claim 6 , wherein the radioactive iodine isotope is selected from the group consisting of 123 I, 125 I and 131 I.

8 . The method of claim 7 , wherein n is 18, and the radioactive iodine isotope is 123 I, 125 I or 131 I (the compound is [ 123 I]-CLR1404, [ 125 I]-CLR1404 or [ 131 I]-CLR1404).

9 . The method of claim 6 , wherein the malignant pediatric solid tumor cells are selected from the group consisting of neuroblastoma (NB) cells, Ewings sarcoma (EWS) cells, osteosarcoma (OS) cells, retinoblastoma (RB) cells, Wilms' tumor (WT) cells, and pediatric brain tumor cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2021
From: BEDNARZ, BRYAN; OTTO, MARIO; WEICHERT, JAMEY; BAIU, DANA
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 057619/0607 →
Continuity (3)
Continuation 15647557 · Jul 12, 2017
Provisional Application 62361888 · Jul 13, 2016
Related Publication 20220008442A1 · Jan 13, 2022
References Cited (20)
US 6255519B1 · Counsell et al. · 2001 [cited by applicant]
US 8535641B2 · Weichert et al. · 2013 [cited by applicant]
US 8877159B2 · Weichert et al. · 2014 [cited by applicant]
US 9339564B2 · Weichert et al. · 2016 [cited by applicant]
US 9550002B2 · Weichert et al. · 2017 [cited by applicant]
US 10004818B2 · Weichert et al. · 2018 [cited by applicant]
US 10736949B2 · Weichert et al. · 2020 [cited by applicant]
US 11147823B2 · Otto · 2021 [cited by examiner]
US 20060013767A1 · Weichert · 2006 [cited by examiner]
US 20140030187A1 · Weichert et al. · 2014 [cited by applicant]
WO 2009027706A2 · 2009 [cited by applicant]
WO 2016081203A2 · 2016 [cited by applicant]
Kiratli et al. Nuclear Medicine in Pediatric and Adolescent Tumors Seminars in Nuclear Medicine vol. 46, Issue 4, Jul. 2016, pp. 308-323 Available online May 26, 2016. (Year: 2016). [cited by examiner]
Brechbiel et al., “Bifunctional Chelates for Metal Nuclides” Q J Nucl Med Mol Imaging, HHS Public Access Author manuscript; available in PMC, pp. 1-17, PMCID: PMC2693392, (Jun. 9, 2009). [cited by applicant]
Cai et al., “Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals”, J. Label Compd. Radiopharm, 57(4):224-230, (Apr. 2014). [cited by applicant]
Fonge et al., “Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles”, Journal of Control Release, 157(3):366-374, (Feb. 2012). [cited by applicant]
Kline et al., “Solid Tumors in Children”, Journal of Pediatric Nursing, 18(2):96-102, (Apr. 2003). [cited by applicant]
Marino et al., “Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog LR1404 in neuroblastoma”, Am J Cancer Res, 5(11):3422-3435, (Nov. 2015). [cited by applicant]
Shukla et al., “Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways”, Clin Cancer Res; 18(3):… [cited by applicant]
Weichert, Jamey P., et al., “Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy,” Science Translational Medicine, 6(240):1-10, (Jun. 11, 2014). [cited by applicant]